Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Rhea-AI Summary
Seres Therapeutics (Nasdaq: MCRB) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:30 a.m. ET. A live webcast will be accessible via the company’s Investors and News "Events and Presentations" page and will be available for replay after the event.
The presentation offers investors a real-time update opportunity and a post-event replay for later review.
Positive
- None.
Negative
- None.
News Market Reaction – MCRB
In the Nov 24 session, MCRB declined 4.18%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET.
A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at http://www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
